VBI Vaccines Reports Positive Results Of Multiple Preclinical Studies For Several COVID-19 Variants
Biopharmaceutical company VBI Vaccines Inc. (VBIV) announced Wednesday positive results from multiple preclinical studies against several COVID-19 variants of concern as well as the initiation of dosing in the Phase 1b portion of the ongoing clinical study of VBI’s SARS-CoV-2 vaccine candidates in approximately 80 adults age 18-54.
VBI’s coronavirus pipeline includes multiple vaccine candidates developed using its proprietary enveloped virus-like particle (eVLP) technology platform. Its objective is to increase the breadth of protection against known and emerging variants of COVID-19. The lead vaccine candidates include VBI-2902 eVLP candidate, VBI-2905 eVLP candidate and VBI-2901 Trivalent eVLP candidate.
The new preclinical data from an ongoing Phase 1b clinical study demonstrates that VBI-2905 induced robust neutralizing and antibody binding activity, as a 2-dose course and as a single booster dose, against COVID-19 and variants of concern including Beta and Delta
The first subject was dosed in Phase 1b portion of ongoing study to assess VBI-2905 as (i) a 1-dose booster in individuals previously immunized with an mRNA vaccine, and (ii) a primary 2-dose series in unvaccinated individuals. The initial VBI-2905 data is expected in early Q1 2022, subject to speed of enrolment.
Data also demonstrates that trivalent VBI-2901 induced robust and consistent levels of immunity against the ancestral COVID-19 strain and a panel of variants including Beta, Delta, Kappa, and Lambda. The company is expected to initiate the first clinical study in the first half of 2022.
As previously announced in June 2021, the VBI-2902 eVLP candidate demonstrated robust immunogenicity and a clean safety profile in the Phase 1a portion of the clinical study.
Source: Read Full Article